

QT VASCULAR LTD.
(Company Registration No. 201305911K)
(Incorporated in Singapore)

- (1) PROPOSED ACQUISITION OF 60% OF THE HEALTHCARE GROUP;
- (2) PROPOSED DIVERSIFICATION INTO THE NEW BUSINESSES;
- (3) PROPOSED ALLOTMENT AND ISSUE OF 4,055,555,556 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY TO THE INVESTORS PURSUANT TO THE PROPOSED SUBSCRIPTION AT AN ISSUE PRICE OF S\$0.0018 PER SUBSCRIPTION SHARE;
- (4) PROPOSED TRANSFER OF CONTROLLING INTEREST IN THE COMPANY TO THE INVESTORS; AND
- (5) PROPOSED DISTRIBUTION

- ELECTRONIC DESPATCH OF CIRCULAR

*Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in QT Vascular Ltd.'s ("**Company**") circular dated 24 December 2021 electronically despatched by the Company today ("**Circular**").*

1. INTRODUCTION

1.1 Further to the previous announcements by the Company dated 25 May 2021, 18 November 2021, 19 November 2021, 30 November 2021, 2 December 2021, 16 December 2021 and 22 December 2021, the Board of Directors of the Company wishes to announce that the Company has today electronically despatched the Circular to Shareholders to provide Shareholders with information relating to:

- (a) the Proposed Acquisition of 60% of the Healthcare Group;
- (b) the Proposed Diversification into the New Businesses;
- (c) the proposed allotment and issue of 4,055,555,556 new ordinary Shares in the capital of the Company to the Investors pursuant to the Proposed Subscription;
- (d) the Proposed Transfer of Controlling Interest in the Company to the Investors; and
- (e) the Proposed Distribution,

(collectively, the "**Proposed Transactions**").

1.2 The Proposed Transactions are inter-conditional (for reasons as further detailed under paragraph 1.10 of the Circular) and subject to the approval of the Shareholders at the forthcoming EGM to be held on 8 January 2022 at 9.30 a.m..

2. EXTRAORDINARY GENERAL MEETING AND CIRCULAR

2.1 Details of the Proposed Transactions are set out in the attached Circular to provide Shareholders with information relating to the Proposed Transactions, including the rationale for and benefits thereof to the Group, and to seek Shareholders' approval for the Proposed Transaction at the forthcoming EGM.

The Circular has been made available on SGXNET and the Company's corporate website and may be accessed at <https://www.sgx.com/securities/company-announcements> and <https://qtvascular.com/>.

3. CAUTION IN TRADING

SHAREHOLDERS AND OTHER INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY AS THERE IS NO CERTAINTY OR ASSURANCE THAT THE PROPOSED TRANSACTIONS WILL BE CONSUMMATED, AS COMPLETION REMAINS SUBJECT TO SATISFACTION OF ALL CONDITIONS PRECEDENT THEREUNDER. SHAREHOLDERS AND OTHER INVESTORS ARE ADVISED TO READ ANY ANNOUNCEMENTS BY THE COMPANY CAREFULLY. THEY SHOULD CONSULT THEIR STOCKBROKERS, BANK MANAGERS, SOLICITORS, ACCOUNTANTS, TAX ADVISORS OR OTHER PROFESSIONAL ADVISORS IF THEY ARE IN ANY DOUBT AS TO THE ACTIONS THEY SHOULD TAKE.

BY ORDER OF THE BOARD

Sho Kian Hin
Director
24 December 2021

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.